Open AccessSynthetic consortia of nanobody‐coupled and formatted bacteria for prophylaxis and therapy interventions targeting microbiome dysbiosis‐associated diseases and co‐morbidities
Author(s) -
Timmis Kenneth,
Timmis James Kenneth,
Brüssow Harald,
Fernández Luis Ángel
Publication year - 2019
Publication title -
microbial biotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.287
H-Index - 74
ISSN - 1751-7915
DOI - 10.1111/1751-7915.13355
Subject(s) - dysbiosis , microbiome , bacteria , medicine , psychological intervention , microbiology and biotechnology , immunology , biology , computational biology , intensive care medicine , bioinformatics , genetics , psychiatry
Designed nanobody‐linked synthetic consortia for microbiota dysbiosis therapies. A. Nanobodies (Nb) are selected for specific antigens on target bacteria destined for a synthetic therapy consortium that may consist of two (B) or multiple (C) members. For the treatment of dysbiosis co‐morbidities requiring two functionally distinct consortia, these may be linked through a common member to generate a single bi‐functional microbiota therapy (D).